Livanova Plc Stock Price, News & Analysis

LivaNova (Nasdaq: LIVN) reported strong Q2 2025 results and raised its full-year guidance. The company achieved revenue of $352.5 million, representing a 10.7% reported growth and 10.3% organic growth. Q2 2025 adjusted diluted EPS reached $1.05, up from $0.93 in Q2 2024.

The company's Cardiopulmonary segment grew 14.7% to $199.3 million, while Neuromodulation increased 6.2% to $151.7 million. LivaNova raised its 2025 guidance, now expecting revenue growth of 8.0-9.0% on a constant-currency basis and adjusted EPS of $3.70-$3.80.

Notable developments include initiating CMS reconsideration for VNS Therapy coverage in treatment-resistant depression and publishing positive long-term data for drug-resistant epilepsy treatment.

LivaNova (Nasdaq: LIVN), a leading medical technology company, has scheduled its second-quarter 2025 earnings conference call for August 6, 2025, at 1 p.m. London time (8 a.m. EDT). The company will release its Q2 2025 financial results before the call.

Investors can access the audiocast at www.livanova.com/events. For telephone access, U.S. participants should dial +1 833 470 1428, while international callers can use +1 929 526 1599 with access code 460430. A replay will be available on LivaNova's website for 90 days after the call.

LivaNova (LIVN) has announced the completion of its CORE-VNS study, demonstrating significant effectiveness of VNS Therapy for treating drug-resistant epilepsy (DRE) in both children and adults. The 36-month study, involving over 800 patients worldwide, showed remarkable seizure reduction rates. In children aged 4-18, focal impaired awareness motor seizures decreased by 87%, while focal to bilateral tonic-clonic seizures showed a 100% median reduction. Among all patients, including adults, 34% achieved complete freedom from focal impaired awareness motor seizures, with an 80% median reduction. Additionally, 49% reported complete freedom from focal to bilateral tonic-clonic seizures, with a 95% median reduction. The study maintained an impressive 82% patient retention rate and showed effectiveness as early as three months post-implantation, with continued improvements throughout the study period.

LivaNova (LIVN) has announced significant 24-month data from their CORE-VNS study published in Epilepsia, showing remarkable effectiveness of VNS Therapy in treating drug-resistant epilepsy (DRE). The study demonstrated a 77% median reduction in generalized tonic-clonic (GTC) seizures at 24 months, with 43% of participants achieving seizure freedom. The study involved patients with a median 10-year epilepsy duration, with 90% diagnosed before age 18. Notably, patients showed early response with 52% seizure reduction at 3 months. The study population had previously failed a median of six anti-seizure medications, with some trying up to 20 different treatments. The research included over 800 epilepsy patients worldwide, with 115 specifically having drug-resistant epilepsy and generalized seizures at baseline.

LivaNova (LIVN) has initiated the process with CMS to seek Medicare coverage reconsideration for VNS Therapy in treatment-resistant depression (TRD) patients. The company's request is supported by five critical peer-reviewed articles featuring RECOVER study data, along with strong 24-month clinical outcomes. The data shows VNS Therapy's durability, with 81.3% of patients maintaining benefits at 24 months, and response rates increasing from 40.2% at 12 months to 51.6% at 24 months. Additional analyses revealed 43% higher odds of meaningful improvement in suicidal ideation compared to the control group, with separation visible as early as three months. The RECOVER study, completed in March 2024, demonstrated that VNS Therapy improves symptoms, function, and quality of life in TRD patients who had previously failed multiple treatments, including ECT and TMS.

LivaNova PLC (Nasdaq: LIVN), a global medical technology company, announced that CEO Vladimir Makatsaria will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York on June 5, 2025, at 3:10 p.m. ET. The presentation will be accessible via webcast on LivaNova's website, with replay available for 90 days after the event.

LivaNova, headquartered in London, has approximately 2,900 employees and operates in over 100 countries, focusing on neurological and cardiac medical solutions. The company builds on nearly five decades of experience in providing life-changing medical technologies.

LivaNova (LIVN) has announced promising 12-month data from its OSPREY clinical trial for the aura6000™ System, a device treating moderate to severe obstructive sleep apnea (OSA). The study showed a 65% responder rate after 12 months, with significant improvements in key metrics: 68% reduction in both apnea-hypopnea index (AHI) and oxygen desaturation index (ODI). The trial demonstrated rapid onset and sustained improvement, with 25% of patients responding on day one and 50% by month three. The aura6000 System uses proximal hypoglossal nerve stimulation with six electrodes, offering customized treatment. Notably, OSPREY included patients with higher OSA severity, higher BMI, and complete concentric collapse risk compared to similar trials. The company has completed its FDA premarket approval submission, with no serious adverse device-related or procedure-related events reported during the study.

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, has scheduled its first-quarter 2025 earnings conference call for Wednesday, May 7, 2025 at 1 p.m. London time (8 a.m. Eastern Time). The company will release its Q1 2025 financial results before the call.

Investors can access the audiocast through www.livanova.com/events, with recommended login 10 minutes before the start. For telephone access, U.S. participants should dial +1 833 470 1428, while international callers can use +1 929 526 1599, with access code 047836. A replay will remain available on the company website for 90 days after the call.

LivaNova PLC (Nasdaq: LIVN) reported strong financial results for Q4 and full-year 2024, with full-year revenue reaching $1.25 billion, an 8.7% increase on a reported basis. The company achieved Q4 revenue of $321.8 million, up 3.8% reported and 6.8% organic compared to the prior year.

Full-year 2024 U.S. GAAP diluted EPS was $1.16, while adjusted diluted EPS reached $3.38. The company generated $183 million in operating cash flow and $162.9 million in adjusted free cash flow.

For 2025, LivaNova expects revenue growth of 5-6% on a constant-currency basis and 6-7% on an organic basis, with adjusted diluted EPS projected between $3.65-$3.75.

The company announced positive clinical milestones, including the OSPREY study for sleep apnea meeting its endpoints and publication of VNS Therapy data for treatment-resistant depression showing clinically meaningful therapeutic effects.